

Modelling the effectiveness of isolation strategies for managing mpox outbreaks with variable infectiousness profiles

AUTHORS:

Yong Dam Jeong¹, Takara Nishiyama¹, Hyeongki Park¹, Masahiro Ishikane², Noriko Iwamoto², Kazuyuki Aihara³, Koichi Watashi⁴, Eline Op de Coul⁵, William S Hart^{1,6}, Robin N Thompson⁶, Norio Ohmagari², Jacco Wallinga^{5,7}, Shingo Iwami^{1,3,8,9,10,11,12,†,*} and Fuminari Miura^{5,13,†,*}

AFFILIATIONS:

¹interdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan. ²Disease Control and Prevention Centre, National Centre for Global Health and Medicine, Tokyo, Japan. ³International Research Center for Neurointelligence, The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Tokyo, Japan. ⁴Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan. ⁵Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. ⁶Mathematical Institute, University of Oxford, Oxford, OX2 6GG, UK. ⁷Department of Biomedical Data Sciences, Leiden University Medical Center (LUMC), Leiden, the Netherlands. ⁸Institute of Mathematics for Industry, Kyushu University, Fukuoka, Japan. ⁹Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan. ¹⁰Interdisciplinary Theoretical and Mathematical Sciences Program (iTHEMS), RIKEN, Saitama, Japan. ¹¹NEXT-Ganken Program, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan. ¹²Science Groove Inc., Fukuoka, Japan. ¹³Center for Marine Environmental Studies (CMES), Ehime University, Ehime, Japan.

†These authors contributed equally to this study.

*To whom correspondence may be addressed.

Email: iwami.iblab@bio.nagoya-u.ac.jp (S.I.) and fuminari.miura@rivm.nl (F.M.)

1 **Abstract**

2 The global outbreak of mpox (formerly monkeypox) in 2022 raised public awareness
3 about the disease. The ensuing sporadic outbreaks in 2023 highlighted the importance of
4 sustaining nonpharmaceutical interventions, such as case isolation and contact tracing. Using
5 viral load data, we developed a modelling framework to characterize the various infectiousness
6 profiles of infected individuals. We used this model to examine the potential effectiveness of two
7 different possible isolation rules: specifically, rules permitting infected individuals to stop isolating
8 after either a fixed-duration or following negative tests for infection. Our analysis showed large
9 individual variations in the duration of viral shedding, ranging from about 23 to 50 days. The risk
10 of infected individuals ending isolation too early (i.e., while they remained an infection risk) was
11 estimated to be about 5% after 3 weeks of isolation. Unnecessary isolation after the end of the
12 infectious period could be reduced by use of a testing-based rule. These findings support the
13 choice of a 3-week isolation period following symptom onset if a fixed-duration rule is used, but
14 also demonstrate how testing can mitigate unnecessarily prolonged isolation for those who have
15 shorter infectious periods.

16 **Main Text**

17 Since May 2022, a global outbreak of mpox (formerly monkeypox) has spread primarily
18 among men who have sex with men (MSM), first in European and North American countries, and
19 later in other regions¹. Although growth of the outbreak was initially rapid, the global trend in
20 reported cases changed around the summer of 2022 and has been declining ever since². Recent
21 studies have suggested that the case saturation in many countries may be explained largely by
22 infection-derived immunity accumulated among individuals who have many sexual partners³,
23 and the following decline in cases may have been accelerated by vaccination campaigns or
24 behavioral changes^{4,5}. However, since the beginning of 2023, sporadic outbreaks have been
25 reported, mainly in Asian countries, which were least affected by the 2022 outbreak and where
26 vaccination campaigns had not yet been initiated, leading to a substantial number of individuals
27 remaining at risk of infection⁶. There are also reports of some breakthrough infections and
28 reinfections in European countries^{7,8}. These findings warrant caution against a resurgence of
29 mpox and highlight the importance of maintaining nonpharmaceutical interventions (NPIs).

30 One essential NPI is case isolation. The effectiveness of isolation has been extensively
31 studied in the context of COVID-19^{9,10} and other diseases^{11,12}. In general, if cases are detected
32 earlier (e.g., via contact tracing) and isolation begins sooner, a larger proportion of onward
33 transmissions can be prevented¹³. When determining the end of isolation, later is always safer,
34 as a longer isolation period minimizes the risk of releasing individuals who remain infectious.
35 However, case identification may require a substantial public health investigation effort, and
36 redundant isolation induces societal cost and burden for individuals^{14,15}. Furthermore, more
37 stringent control strategies may also lead to reduced efficacy due to non-adherence¹⁶. To
38 mitigate these burdens, testing-based rules were applied during the COVID-19 pandemic^{17,18},
39 which typically involved ending isolation following a specified number of successive negative
40 PCR or antigen test results. Individual-level viral load data have been used to balance the
41 effectiveness and cost of isolation rules¹⁹, which is key to sustainable implementation.

42 Current guidelines for mpox generally suggest individuals who are exposed to the virus
43 quarantine for about three weeks^{18,20-23} and refrain from sexual contact for 12 weeks after the
44 end of isolation²⁰. The three-week monitoring period is based on the estimated incubation
45 period^{24,25}, in which more than 98% of cases show symptoms within 21 days of exposure.
46 Although the exact duration of the infectious period is unclear, several studies have investigated
47 serial intervals (i.e., the time interval between symptom onset dates of primary and secondary
48 cases) and have suggested that, for symptomatic cases, more than 90% of transmission occurs
49 within two weeks of symptom onset^{26,27}. Recent findings have also indicated that there might be
50 considerable heterogeneity in the infectious period between infected individuals. For example,
51 there is substantial variation in observed serial intervals²⁶, and some confirmed cases in Europe
52 exhibited prolonged viral shedding in their bodily fluids^{28,29}. Consequently, isolation rules that do
53 not account for heterogeneity between infected individuals (e.g. rules based on isolating for a
54 fixed period following symptom onset) may lead to either a risk of ending isolation too early for
55 those who are still infectious, or an unnecessarily long isolation period for those who are no
56 longer infectious.

57 In this study, we first characterize individual infectiousness profiles among mpox cases by
58 analyzing longitudinal viral load data. We describe the time course of virus shedding using a
59 mathematical model that captures individual heterogeneity in the duration of viral clearance. We
60 then stratify the population according to the characterized shedding profiles and evaluate the
61 effectiveness of two different isolation rule types: a fixed-duration rule and a testing-based rule
62 (i.e., a tailored rule for individuals who test negative several times). Our study provides an
63 approach to quantify both the risk of ending isolation too early and the period for which infected
64 individuals are isolated but do not pose an infection risk. Our model can be used by policy makers
65 to inform decision making, allowing isolation strategies to be determined that balance cost and
66 effectiveness appropriately.

67 **Results**

68 **Analyzed data and model fitting**


69 We conducted a literature review of individual-level mpox patient data and identified a total
70 of 90 mpox cases with lesion samples meeting the inclusion criteria (see **Methods**). All cases
71 were symptomatic, and most of them were reported in Europe. To standardize the collected data,
72 we converted the reported cycle threshold values to viral load (copies/ml) using the conversion
73 formula proposed in a previous study³⁰ (**Supplementary Table 1**). We then fitted the viral
74 clearance model to the longitudinal viral load data from lesion samples (**Extended Data Fig. 1a**
75 and **Supplementary Fig. 1**). Estimated parameters suggested a median viral load of $10^{7.7}$
76 copies/ml (95% CI: $10^{7.3}$ - $10^{8.2}$) at symptom onset. Additionally, a prolonged duration of viral
77 shedding was estimated: the viral load dropped below the detection limit ($10^{2.9}$ copies/ml) 30.9
78 days (95% CI: 23.4-50.6) after symptom onset (**Extended Data Fig. 1bc**). This finding is
79 consistent with previous studies suggesting the persistent presence of mpox viruses in clinical
80 specimens^{28,31}.

81

82 **Stratification for mpox cases**

83 The 90 analyzed mpox cases were stratified into three groups based on their estimated
84 individual parameters using the K-means clustering algorithm: Group 1 (medium risk of
85 transmission), Group 2 (high risk of transmission), and Group 3 (low risk of transmission) (**Fig.**
86 **1a** and **1b**): Group 3 was characterized by a lower viral load at symptom onset and faster
87 clearance, whereas Group 2 was characterized by a higher viral load at symptom onset and
88 slower clearance. In addition, to compare the viral dynamics between the three groups, we
89 conducted statistical tests: Individuals in Group 2 had significantly higher viral loads at symptom
90 onset than individuals in the other groups ($p < 1.0 \times 10^{-3}$ from the Mann-Whitney test). Also,
91 individuals in this group had a larger area under the viral load curve (AUC) ($p < 1.0 \times 10^{-3}$ from
92 the Mann-Whitney test), that is, the total amount of virus excreted between symptom onset and

93 the end of shedding. Viral clearance was significantly faster in Group 3 than in the other groups
94 ($p < 1.0 \times 10^{-4}$ from the Mann-Whitney test) (**Fig. 1c**). To describe the difference in timing of
95 viral clearance, we additionally simulated the probability of detectable virus over time by using
96 the model with estimated parameters for each group (**Fig. 1d**). In all stratified groups, the
97 probability was greater than 90% at 3 weeks after symptom onset. However, in the total group
98 (i.e., a group of all analyzed cases), the probability dropped to 69.9% (95% CI: 67.0-73.2) at 4
99 weeks after symptom onset, which is the upper bound of the isolation period recommended by
100 the CDC²¹. The probability in Group 3 at 4 weeks after symptom onset was 55.3% (95% CI:
101 51.8-55.0), whereas the corresponding probability in Group 2 was 90.6% (95% CI: 88.7-92.1).



102

103 **Fig. 1: Stratification of mpox virus infections.** **a**, Results of K-means clustering of mpox cases
 104 based on estimated individual parameters. Data points indicate individuals and are colored
 105 based on the group that each individual is in. The dimensions represent standardized estimated
 106 model parameters. **b**, Reconstructed individual mpox viral load trajectories in each group are
 107 shown. Group 1, Group 2, and Group 3 represent cases with medium, high, and low risk of
 108 transmission, respectively. **c**, Comparison between groups of: virus at symptom onset (left
 109 panel); area under the viral load curve (AUC), i.e., the total amount of virus shed over time
 110 (middle panel); and duration of viral clearance (right panel), respectively. The Mann-Whitney test
 111 was used to test for significant differences between groups. **d**, Viral clearance in each group.
 112 Probability of detectable virus after symptom onset for each group (left panel). The solid lines
 113 and shaded regions indicate means and 95% confidence intervals, respectively. Bar plots
 114 represent the probabilities for 3 weeks (right upper panel) and 4 weeks (right lower panel) after
 115 symptom onset, respectively.

l16 **Fixed-duration rule**

l17 Under the estimated viral dynamics, we compared two types of rule for ending the isolation
l18 of mpox cases (fixed-duration and testing-based). To assess the effectiveness of the two rules,
l19 we considered three metrics: 1) the risk of prematurely ending isolation, 2) the average infectious
l20 period after ending isolation (where this period was defined to be zero for individuals who isolate
l21 beyond the duration of their infectious period), and 3) the average duration for which individuals
l22 were isolated unnecessarily after the end of their infectious period (which could be positive or
l23 negative). Whether an individual was infectious or not was ascertained based on a viral load
l24 threshold for infectiousness that was obtained from data on viral replication in cell culture^{28,32,33}.

l25 Under a fixed-duration rule of ending isolation 3 weeks after symptom onset, the risk of
l26 ending isolation prematurely in the total group was estimated to be 5.4% (95% CI: 4.1-6.7). The
l27 average duration for which individuals were isolated unnecessarily after the end of their infectious
l28 period was 8.3 days (95% CI: 8.0-8.6). Group 3 had a lower risk of ending isolation prematurely of
l29 0.7% (95% CI: 0.3-1.3), and a longer unnecessary isolation period of 10.4 days (95% CI:
l30 10.2-10.6). However, in Group 2, a higher risk of 16.1% (95% CI: 13.9-18.1) was estimated, with
l31 a shorter unnecessary isolation period of 4.6 days (95% CI: 4.2-4.9). To guarantee a risk of
l32 prematurely ending isolation below 5% and an infectious period after ending isolation shorter than
l33 1 day, we found that the total group, Group 1, Group 2, and Group 3 needed to be isolated for 22,
l34 23, 26, and 17 days, respectively. In this case, the duration for which individuals were isolated
l35 unnecessarily after the end of their infectious period was estimated to be 9.4, 8.1, 9.6, and 6.3
l36 days for the total group, Group 1, Group 2, and Group 3, respectively (**Fig. 2a**).

l37


l38 **Testing-based rule**

l39 For a fixed-duration rule, isolation of mpox cases ends after a fixed time period following
l40 symptom onset, so the three metrics considered here can be calculated based on the isolation
l41 period alone (**Fig. 2a**). By contrast, a testing-based rule is dependent on both the time interval
l42 between tests and the exact criterion used for ending isolation (see **Methods**). Under a criterion in

l43 which isolation ends following two consecutive negative results with daily testing (a criterion
l44 widely used for COVID-19)¹⁷, the total group had a risk of prematurely ending isolation of 52.2%
l45 (95% CI: 49.7-54.6), and the infectious period after ending isolation was calculated to be 2.3 days
l46 (95% CI: 2.1-2.5). Similarly, high risks of prematurely ending isolation, accompanied with an
l47 infectious period after ending isolation longer than 1 day, were estimated in the stratified groups
l48 (first-row and second-row panels in **Fig 2b**).

l49 By varying the criteria (i.e., the required number of consecutive negative results and the
l50 time interval between tests), different testing-based isolation strategies can be tested in terms of
l51 their effects on the three metrics. The risk of prematurely ending isolation and the infectious
l52 period after ending isolation decreased with a longer interval between tests and with a larger
l53 number of consecutive negative results (first-row and second-row panels in **Fig 2b**), whereas the
l54 duration for which individuals were isolated unnecessarily after the end of their infectious period
l55 increased (third-row panels in **Fig 2b**). Under the conditions that the risk of prematurely ending
l56 isolation is lower than 5% and infectious period after ending isolation is shorter than 1 day, the
l57 minimum value of the unnecessary isolation period in the total group was 7.4 days (95% CI:
l58 7.1-7.7) with three consecutive negative results and an interval of 5 days between tests.
l59 Correspondingly, an isolation period of 20.1 days (95% CI: 19.7-20.5) was required on average
l60 (purple triangles in **Fig 2b**). On the other hand, under the same conditions, stricter strategies were
l61 needed for Group 2: four consecutive negative results and an interval of 2 days between tests
l62 were needed to minimize the duration for which individuals were isolated unnecessarily after the
l63 end of their infectious to 8.0 days (95% CI: 7.7-8.2), with a mean isolation period of 20.6 days
l64 (95% CI: 20.1-21.0) (red triangles in **Fig 2b**).

l65



166

167 **Fig 2: Fixed-duration and testing-based rules for different groups. a**, Fixed-duration rules.

168 The risk of prematurely ending isolation for different isolation periods (left panel). The black
 169 horizontal line corresponds to 5%. Infectious period after ending isolation for different isolation
 170 periods (middle panel). The grey horizontal line corresponds to 1 day. The time period for which
 171 individuals were isolated unnecessarily after the end of their infectious period for different
 172 isolation periods (right panel). The circles correspond to the points with the lowest unnecessarily
 173 prolonged isolation period for which the following conditions are satisfied: i) the risk of
 174 prematurely ending isolation was required to be lower than 5% and ii) the infectious period after
 175 ending isolation was required to be shorter than 1 day. The shaded regions in each panel
 176 indicate 95% confidence intervals. b, Testing-based rules. The risk of prematurely ending

l77 isolation (first row of panels), the infectious period after ending isolation (second row of panels),
l78 the isolation period following the end of infectiousness (third row of panels), and the optimal
l79 isolation period (fourth row of panels) are shown for different intervals between PCR tests and
l80 numbers of consecutive negative results necessary to end isolation. The areas surrounded by
l81 black and grey lines are those with 5% or lower risk of prematurely ending isolation and with 1
l82 day or shorter infectious period after ending isolation, respectively. The triangles correspond to
l83 the points with the shortest isolation period following the end of infectiousness for which both
l84 conditions noted above are satisfied. Color keys and symbols apply to all panels. Note that the
l85 estimated values are based on 100 independent simulations.

186 **Comparison between fixed-duration and testing-based rules for ending isolation**

187 To highlight the difference between fixed-duration and testing-based rules for each group,
188 we compared the two types of rule by computing the optimal isolation strategies in which the
189 isolation period following the end of infectiousness is minimized while ensuring that the risk of
190 prematurely ending isolation is less than 5% and the infectious period after ending isolation is less
191 than 1 day. For testing-based rules, the mean isolation period that the optimal strategies then lead
192 to can be computed for each stratified group. In the total group, the optimized fixed-duration and
193 testing-based rules gave isolation periods of 22 and 20.1 days, resulting in minimized
194 unnecessary isolation periods of 9.4 and 7.4 days, respectively (**Extended Data Fig. 2**). In Group
195 2, the testing-based rule led to an unnecessary isolation period that was 1.4 days shorter than the
196 fixed-duration rule, whereas Groups 1 and 3 showed similar unnecessary isolation periods when
197 either rule was applied. However, compared with the fixed-duration rule in the total group, the
198 testing-based rule in Group 3 could reduce the optimal isolation period and the unnecessarily
199 isolation period to 17.1 days and 6.5 days, respectively.

200 As a sensitivity analysis, we varied the assumed infectiousness threshold and investigated
201 the corresponding difference in the period for which individuals were isolated unnecessarily after
202 the end of their infectious period between the two rules (**Supplementary Fig. 2**). When the
203 infectiousness threshold is higher, the corresponding infectious period becomes shorter, leading
204 to a shorter required isolation period and shorter period of unnecessary isolation given the same
205 acceptable risk. Our analysis showed that a higher infectiousness threshold resulted in smaller
206 differences between the two rules for each stratified group (**Supplementary Fig. 2**), which was
207 consistent with our previous findings for COVID-19⁹.

208

209 **Comparison between lesion and other samples for infectiousness after ending isolation**

210 To demonstrate that lesion samples are suitable for designing isolation rules, we
211 compared the viral dynamics that we inferred using lesion samples to analogous results obtained
212 using other samples. Specifically, we used longitudinal viral load data measured in upper

213 respiratory tract, blood, and semen samples from the same mpox cases to estimate mpox virus
214 dynamics in those samples (**Supplementary Table 1** and **Extended Data Fig. 3a**). Following
215 symptom onset, other samples exhibited lower viral loads compared with lesion samples. In
216 particular, at the optimal ending isolation period of 22 days under a fixed-duration rule, the viral
217 load in lesion samples was substantially higher than in other samples (**Extended Data Fig. 3b**).
218 Moreover, we compared the predicted infectiousness when lesion samples and other samples
219 are used by computing the proportion of individuals who remained infectious on day 22 after
220 symptom onset. Around 3% of individuals were estimated to be infectious when lesion samples
221 were used, whereas the viral load never exceeded the infectiousness threshold for the other
222 samples (**Extended Data Fig. 3c**). This suggests that infectious mpox cases may be missed if
223 we implement a testing-based rule with samples other than lesion samples.

224 Discussion

225 In this study, we have compared different strategies that can be implemented to determine
226 when mpox infected individuals stop isolating. If a single population-wide fixed-duration isolation
227 strategy is used, then we found that allowing individuals to end their isolation after a period of
228 three weeks following symptom onset is a reasonable threshold. Under this strategy, more than
229 95% of onward transmissions would be prevented. Our modelling analysis showed that there was
230 individual heterogeneity in viral shedding kinetics, indicating that the use of testing-based rules
231 may reduce the period for which infected individuals with a shorter duration of virus shedding are
232 required to isolate.

233 We observed different shedding kinetics between patients in the analyzed data. We
234 therefore stratified the patients based on their viral load during the decay phase of infection (**Fig.**
235 **1**). Variations in virus shedding may lead to substantial heterogeneity in infectiousness between
236 individuals. For mpox, existing studies have focused on individual variations in the number of
237 sexual contacts or partners^{4,34}, because higher contact rates generally result in a larger number of
238 secondary cases. In contrast, variations in viral shedding have received limited attention to date.
239 Our study found that some mpox cases exhibit a 5–10-day shorter (or longer) duration of virus
240 shedding than the average. Individuals in those groups may thus contribute to virus transmission
241 for shorter (or longer) periods, resulting in a lower (or higher) number of secondary cases. When
242 designing tailored interventions to ensure that the time-dependent reproduction number, R (the
243 average number of secondary cases generated by each infected individual)³⁵, is below one (i.e.,
244 the outbreak is declining), our approach provides a way to incorporate such heterogeneity in the
245 infectious period by using individual viral load as a proxy.

246 For evaluating the risk of transmission following the end of isolation, the use of longitudinal
247 viral load data may be advantageous over symptom-based approaches. One difficulty lies in the
248 inherent uncertainty in self-reported symptoms; many confirmed mpox cases have been found to
249 be not fully aware of their symptoms at the time of reporting³⁶. Viral load data have the potential to
250 provide more objective and quantitative criteria for ending isolation³⁷. If viral load data are used,

251 measuring viral load in lesion samples (rather than the other sample types that we considered) is
252 the safest choice, as lesion samples showed the highest viral load and the longest detectable
253 period (**Extended Data Fig. 3**).

254 Isolation rules need to balance the risk of releasing infectious cases prematurely and the
255 societal burden of extended isolation. Our results indicate that optimized fixed-duration and
256 testing-based rules can result in comparable risk levels if the same rule is applied to all cases. By
257 contrast, the total duration of unnecessary isolation can be reduced using a testing-based rule. It
258 is possible to shorten the isolation period for those with faster viral clearance, leading to a reduced
259 burden at the population level. A testing-based approach may also be beneficial for evaluating the
260 times at which individuals can resume sexual activities. Despite the current recommendation of
261 using a condom for 12 weeks after scabs have fallen off as a precaution²⁰, having additional
262 information about patients' infectiousness would offer reassurance to them and help to prevent
263 discrimination and stigma related to sexual behaviors. As outlined in **Extended Data Fig. 3c**, our
264 assessment revealed that viral load in semen had fallen below the infectiousness threshold by the
265 endpoint of an optimized 22-day isolation period.

266 As with any modelling analysis, there are several limitations to our study. First, our analysis
267 relied on the patient data collected, which may not be representative of all mpox cases in the
268 affected population. The estimated parameters were obtained using data from untreated patients,
269 but in outbreak settings antiviral drugs such as tecovirimat may be provided to infected individuals
270 and used prophylactically. Further investigations into the association between clinical
271 characteristics of patients, treatments, and viral load would be needed for a more granular
272 understanding of heterogeneous infectiousness profiles. This may enable, for example, different
273 fixed-duration isolation periods to be specified for individuals with different characteristics.
274 Second, the association between mpox viral load and infectiousness needs to be understood
275 more deeply. Specifically, based on experimental data on viral culturability, we used 10^6
276 copies/ml as the infectiousness threshold value in main analysis; however, this involves
277 uncertainty^{28,32,33}. Accordingly, we performed sensitivity analyses (**Supplementary Fig. 2**) and

278 found similar results regardless of the assumed threshold value. Last, our analysis did not capture
279 external sources of uncertainty affecting the false-negative rate of testing. In practical settings,
280 imperfect swab sampling, especially with self-collection, could occur (leading to differential test
281 specificity/sensitivity). There may also be cases who repeatedly get tested until obtaining a
282 negative result, as occurred during the COVID-19 pandemic³⁸. Such challenges need to be
283 considered when implementing testing-based rules.

284 In conclusion, this study provides empirical evidence for heterogeneity in virus shedding
285 kinetics and infectiousness among mpox cases and describes the impact of such heterogeneity
286 on the effectiveness of different isolation rules. Rules that recommend isolating following a fixed
287 period after being exposed to the virus are straightforward to apply, and can be effective at
288 preventing transmission. Rules that are instead based on obtaining negative test results prior to
289 ending isolation are more nuanced and can have advantages, for example by reducing the
290 period for which some individuals are required to isolate after they are no longer infectious.
291 Careful consideration of the benefits and drawbacks of different strategies for ending isolation is
292 essential. Ensuring sustainable implementation of NPIs remains key to responding effectively to
293 future outbreaks of mpox.

294 **METHODS**

295 **Viral load data**

296 We searched the literature for longitudinal data from mpox cases meeting the following
297 criteria: 1) viral load was measured at least at two different time points; 2) viral load was measured
298 in different samples including lesion samples; and 3) patients did not receive any antivirals (as our
299 model does not consider antiviral treatment). A total of 7 publications met those criteria, and 90
300 mpox cases were identified. We used only de-identified data from published studies and thus
301 ethics approval was not required.

302

303 **Modelling mpox viral clearance and parameter estimation**

304 Using the viral load data, we parameterized a mathematical model of temporal viral
305 clearance dynamics in each infected individual. For this, we employed an exponential decay
306 model, which was previously utilized in an mpox study²⁸:

$$\frac{dV(t)}{dt} = -\delta V(t),$$

307 where the variable $V(t)$ is the viral RNA load (copies/ml) at time t and parameter δ represents
308 the viral clearance rate. Note that the timescale is time after symptom onset; $t = 0$ is thus the
309 date on which symptoms of mpox first began. $V(0)$ is the initial viral load at symptom onset.

310 A nonlinear mixed-effect model was used to estimate the parameters δ and $V(0)$ ^{9,10}. This
311 approach captures the heterogeneity in the viral dynamics by including both a fixed effect (the
312 shared effect among individuals, i.e., population parameter) and a random effect (the
313 individual-level effect) in each parameter. Population parameters and the standard deviation of
314 random effects were estimated by using the Stochastic Approximation Expectation Maximization
315 algorithm to compute the maximum likelihood estimator of the parameters, assuming a Gaussian
316 distribution (mean 0 and variance σ^2) for the residuals (i.e., differences between predicted log
317 viral load and measured log viral load) to quantify the error used in our simulations³⁹. Individual

318 parameters were subsequently computed using Markov Chain Monte Carlo (MCMC). The
319 estimation procedures were performed using MONOLIX 2023R1 (www.lixoft.com).

320

321 **Clustering algorithm to stratify mpox cases**

322 We stratified the mpox cases using the K-means clustering algorithm⁴⁰, which finds cluster
323 assignments by minimizing the sum of squared Euclidean distances between estimated
324 parameter sets. We first standardized the estimated parameters, since the two parameters in the
325 viral clearance model have different units. Then, the algorithm partitioned the set of estimated
326 individual parameters into k clusters. The optimal number of clusters was determined by the
327 Silhouette method⁴¹.

328

329 **Simulation of viral dynamics and different rules for ending isolation**

330 To account for individual variability in viral dynamics when determining the optimal duration
331 of isolation, we simulated the predicted viral load, $V(t)$, for 1000 virtual patients by running the
332 viral clearance model. Parameter sets for each virtual patient were sampled from distributions of
333 estimated model parameters. The measured viral load, $\hat{V}(t)$, was obtained from the following
334 equation: $\log_{10} \hat{V}(t) = \log_{10} V(t) + \varepsilon$, $\varepsilon \sim N(0, \sigma^2)$, where ε is the error term. For each individual,
335 the residuals were calculated at all measurement time points, and by fitting the Gaussian
336 distribution to all computed residuals, the variance of error, σ^2 , was estimated. For parameter
337 sets for virtual patients in each stratified group, we used individual parameters drawn from
338 conditional distributions (i.e., distributions conditioned on the observed data and the estimated
339 population parameters) characterizing the estimated parameters for individuals in each group, as
340 estimated in the MCMC procedure.

341 Under a fixed-duration rule, it was assumed that isolation would end at a specified time
342 following symptom onset. On the other hand, under testing-based rules using PCR tests, isolation
343 ended when a given number of consecutive negative results was met with a given interval
344 between tests. Here, we assumed that patients began to take tests immediately following

345 symptom onset. To simulate various situations, we varied the interval between tests (from 1 to 5
346 days) and the number of consecutive negative results (from 1 to 5 times). To ascertain individuals'
347 infectious periods, a viral load threshold of infectiousness was considered. If the viral load of a
348 patient was above the threshold, the patient was considered as being infectious. The threshold
349 values considered were obtained from studies on viral replication in cell culture^{28,32,33}. In this study,
350 we set 10^6 copies/ml as the main threshold value. However, this value is still uncertain and thus
351 we also considered different threshold values from 10^5 copies/ml to 10^7 copies/ml as sensitivity
352 analyses. For the evaluation of different rules, three metrics were computed: 1) risk of
353 prematurely ending isolation, 2) infectious period after ending isolation, and 3) unnecessarily
354 prolonged isolation period. The first metric gives the probability of releasing patients while they
355 are still infectious. The second metric is defined as the mean number of days for which patients
356 remain infectious after they are released from isolation (defined to be zero for an individual who is
357 no longer infectious when released from isolation). The third metric gives the mean difference
358 between the time when patients are no longer infectious and the time at which their isolation
359 ends^{9,10} (which is negative for individuals who are infectious beyond the end of isolation).
360 Specifically, the risk of prematurely ending isolation was computed as
361 $\sum_i I(V_i(\tau_i) > \text{Infectiousness threshold})/1000$, where I is the indicator function, V_i is the
362 predicted viral load of patient i , and τ_i is the time when isolation of patient i ends. We computed
363 the infectious period after ending isolation by use of the following formula: $\sum_i \max(0, \bar{\tau}_i - \tau_i)/$
364 1000 , where $\bar{\tau}_i$ indicates the time when the predicted viral load of patient i drops below the
365 infectiousness threshold. Finally, the unnecessarily prolonged isolation period was calculated as
366 $\sum_i (\tau_i - \bar{\tau}_i)/1000$. By running 100 simulations (1000 patients for each simulation), we reported the
367 mean and 95% confidence intervals for distributions of those three metrics, respectively. All
368 analyses were conducted using the statistical computing software R (version 4.2.3).

369 **LIST OF SUPPLEMENTARY MATERIALS**

370 **Supplementary Fig. 1:** Estimated individual viral load trajectory for each mpox case with lesion
371 samples

372 **Supplementary Fig. 2:** Comparison between fixed-duration and testing-based rules depending
373 on different infectiousness thresholds

374 **Supplementary Fig. 3:** Estimated individual viral load trajectory for each mpox case with different
375 samples

376 **Supplementary Table 1:** Summary of mpox viral load data with different samples

377 **Supplementary Table 2:** Estimated fixed effect parameters, standard deviation of random effect,
378 and standard deviation of error in mpox viral loads for each sample

379

380 REFERENCES

- 381 1 Vaughan, A. M. *et al.* A large multi-country outbreak of monkeypox across 41 countries in the
 382 WHO European Region, 7 March to 23 August 2022. *Euro Surveill* **27**,
 383 doi:10.2807/1560-7917.ES.2022.27.36.2200620 (2022).
- 384 2 World Health Organization. 2022-23 Mpox Outbreak: Global Trends,
 385 <https://worldhealthorg.shinyapps.io/mpox_global/> (2023).
- 386 3 Murayama, H. *et al.* Accumulation of immunity in heavy-tailed sexual contact networks shapes
 387 mpox outbreak sizes. *J Infect Dis*, doi:10.1093/infdis/jiad254 (2023).
- 388 4 Xiridou, M. *et al.* The fading of the mpox outbreak among men who have sex with men: a
 389 mathematical modelling study. *medRxiv*, 2023.2001.2031.23285294,
 390 doi:10.1101/2023.01.31.23285294 (2023).
- 391 5 Brand, S. P. C. *et al.* The role of vaccination and public awareness in forecasts of Mpox incidence
 392 in the United Kingdom. *Nat Commun* **14**, 4100, doi:10.1038/s41467-023-38816-8 (2023).
- 393 6 Endo, A., Jung, S. M. & Miura, F. Mpox emergence in Japan: ongoing risk of establishment in
 394 Asia. *Lancet* **401**, 1923-1924, doi:10.1016/S0140-6736(23)00766-3 (2023).
- 395 7 Thy, M. *et al.* Breakthrough Infections after Postexposure Vaccination against Mpox. *N Engl J*
 396 *Med* **387**, 2477-2479, doi:10.1056/NEJMc2211944 (2022).
- 397 8 Raccagni, A. R. *et al.* Two individuals with potential monkeypox virus reinfection. *Lancet Infect*
 398 *Dis* **23**, 522-524, doi:10.1016/S1473-3099(23)00185-8 (2023).
- 399 9 Jeong, Y. D. *et al.* Revisiting the guidelines for ending isolation for COVID-19 patients. *Elife* **10**,
 400 doi:10.7554/eLife.69340 (2021).
- 401 10 Jeong, Y. D. *et al.* Designing isolation guidelines for COVID-19 patients with rapid antigen tests.
 402 *Nat Commun* **13**, 4910, doi:10.1038/s41467-022-32663-9 (2022).
- 403 11 Muller, J. & Kretzschmar, M. Contact tracing - Old models and new challenges. *Infect Dis Model*
 404 **6**, 222-231, doi:10.1016/j.idm.2020.12.005 (2021).
- 405 12 Alpalhao, M. & Filipe, P. The Impacts of Isolation Measures Against SARS-CoV-2 Infection on
 406 Sexual Health. *AIDS Behav* **24**, 2258-2259, doi:10.1007/s10461-020-02853-x (2020).
- 407 13 Kretzschmar, M. E. *et al.* Impact of delays on effectiveness of contact tracing strategies for
 408 COVID-19: a modelling study. *Lancet Public Health* **5**, e452-e459,
 409 doi:10.1016/S2468-2667(20)30157-2 (2020).
- 410 14 Ash, T., Bento, A. M., Kaffine, D., Rao, A. & Bento, A. I. Disease-economy trade-offs under
 411 alternative epidemic control strategies. *Nat Commun* **13**, 3319, doi:10.1038/s41467-022-30642-8
 412 (2022).
- 413 15 Hossain, M. M., Sultana, A. & Purohit, N. Mental health outcomes of quarantine and isolation for
 414 infection prevention: a systematic umbrella review of the global evidence. *Epidemiol Health* **42**,
 415 e2020038, doi:10.4178/epih.e2020038 (2020).
- 416 16 Leng, T., Hill, E. M., Keeling, M. J., Tildesley, M. J. & Thompson, R. N. The effect of
 417 notification window length on the epidemiological impact of COVID-19 contact tracing mobile
 418 applications. *Commun Med (Lond)* **2**, 74, doi:10.1038/s43856-022-00143-2 (2022).
- 419 17 *Discontinuation of transmission-based precautions and disposition of patients with COVID-19 in*
 420 *healthcare settings (interim guidance)*, <<https://stacks.cdc.gov/view/cdc/88538>> (2020).
- 421 18 *Infection Prevention and Control of Mpox in Healthcare Settings*,
 422 <<https://www.cdc.gov/poxvirus/mpox/clinicians/infection-control-healthcare.html>> (2022).
- 423 19 Maya, S. & Kahn, J. G. COVID-19 testing protocols to guide duration of isolation: a
 424 cost-effectiveness analysis. *BMC Public Health* **23**, 864, doi:10.1186/s12889-023-15762-0 (2023).
- 425 20 UK Health Security Agency. *Mpox (monkeypox): people who are isolating at home*,
 426 <[https://www.gov.uk/guidance/guidance-for-people-with-monkeypox-infection-who-are-isolating](https://www.gov.uk/guidance/guidance-for-people-with-monkeypox-infection-who-are-isolating-at-home)
 427 [-at-home](https://www.gov.uk/guidance/guidance-for-people-with-monkeypox-infection-who-are-isolating-at-home)> (2022).
- 428 21 Centers for Disease Control and Prevention (CDC). *Isolation and Prevention Practices for*
 429 *People with Mpox*, <<https://www.cdc.gov/poxvirus/mpox/clinicians/isolation-procedures.html>>
 430 (2023).

- 131 22 *European Centre for Disease Prevention and Control. Guidance on ending the isolation period*
 132 *for people with COVID-19, third update,*
 133 [134 *<https://www.ecdc.europa.eu/en/publications-data/covid-19-guidance-discharge-and-ending-isolat*](https://www.ecdc.europa.eu/en/publications-data/covid-19-guidance-discharge-and-ending-isolat)
 135 [136 *ion>*](https://www.ecdc.europa.eu/en/publications-data/covid-19-guidance-discharge-and-ending-isolat) (2022).
- 137 23 *National Institute for Public Health and the Environment. Information letter for a person with*
 138 *monkeypox,* [139 *<https://lci.rivm.nl/information-letter-person-monkeypox>*](https://lci.rivm.nl/information-letter-person-monkeypox) (2022).
- 140 24 Miura, F. *et al.* Estimated incubation period for monkeypox cases confirmed in the Netherlands,
 141 May 2022. *Euro Surveill* **27**, doi:10.2807/1560-7917.ES.2022.27.24.2200448 (2022).
- 142 25 Guzzetta, G. *et al.* Early Estimates of Monkeypox Incubation Period, Generation Time, and
 143 Reproduction Number, Italy, May-June 2022. *Emerg Infect Dis* **28**, 2078-2081,
 144 doi:10.3201/eid2810.221126 (2022).
- 145 26 Miura, F. *et al.* Time scales of human mpox transmission in the Netherlands. *J Infect Dis*,
 146 doi:10.1093/infdis/jiad091 (2023).
- 147 27 Madewell, Z. J. *et al.* Serial Interval and Incubation Period Estimates of Monkeypox Virus
 148 Infection in 12 Jurisdictions, United States, May-August 2022. *Emerg Infect Dis* **29**, 818-821,
 149 doi:10.3201/eid2904.221622 (2023).
- 150 28 Suner, C. *et al.* Viral dynamics in patients with monkeypox infection: a prospective cohort study
 151 in Spain. *Lancet Infect Dis* **23**, 445-453, doi:10.1016/S1473-3099(22)00794-0 (2023).
- 152 29 Gaspari, V. *et al.* Monkeypox Outbreak 2022: Clinical and Virological Features of 30 Patients at
 153 the Sexually Transmitted Diseases Centre of Sant' Orsola Hospital, Bologna, Northeastern Italy. *J*
 154 *Clin Microbiol* **61**, e0136522, doi:10.1128/jcm.01365-22 (2023).
- 155 30 Luciani, L. *et al.* A novel and sensitive real-time PCR system for universal detection of
 156 poxviruses. *Sci Rep* **11**, 1798, doi:10.1038/s41598-021-81376-4 (2021).
- 157 31 Kapmaz, M. *et al.* A complicated case of monkeypox and viral shedding characteristics. *J Infect*
 158 **86**, 66-117, doi:10.1016/j.jinf.2022.10.020 (2023).
- 159 32 Saijo, M. *et al.* Diagnosis and assessment of monkeypox virus (MPXV) infection by quantitative
 160 PCR assay: differentiation of Congo Basin and West African MPXV strains. *Jpn J Infect Dis* **61**,
 161 140-142 (2008).
- 162 33 Norz, D. *et al.* Evidence of surface contamination in hospital rooms occupied by patients infected
 163 with monkeypox, Germany, June 2022. *Euro Surveill* **27**,
 164 doi:10.2807/1560-7917.ES.2022.27.26.2200477 (2022).
- 165 34 Endo, A. *et al.* Heavy-tailed sexual contact networks and monkeypox epidemiology in the global
 166 outbreak, 2022. *Science* **378**, 90-94, doi:10.1126/science.add4507 (2022).
- 167 35 Thompson, R. N. *et al.* Improved inference of time-varying reproduction numbers during
 168 infectious disease outbreaks. *Epidemics* **29**, 100356, doi:10.1016/j.epidem.2019.100356 (2019).
- 169 36 De Baetselier, I. *et al.* Retrospective detection of asymptomatic monkeypox virus infections
 170 among male sexual health clinic attendees in Belgium. *Nat Med* **28**, 2288-2292,
 171 doi:10.1038/s41591-022-02004-w (2022).
- 172 37 Ejima, K. *et al.* Estimation of the incubation period of COVID-19 using viral load data. *Epidemics*
 173 **35**, 100454, doi:10.1016/j.epidem.2021.100454 (2021).
- 174 38 Mouliou, D. S. & Gourgoulis, K. I. False-positive and false-negative COVID-19 cases:
 175 respiratory prevention and management strategies, vaccination, and further perspectives. *Expert*
 176 *Rev Respir Med* **15**, 993-1002, doi:10.1080/17476348.2021.1917389 (2021).
- 177 39 Kuhn, E. & Lavielle, M. Maximum likelihood estimation in nonlinear mixed effects models.
 178 *Computational statistics & data analysis* **49**, 1020-1038 (2005).
- 179 40 Sammut, C. & Webb, G. I. *Encyclopedia of machine learning*. (Springer Science & Business
 180 Media, 2011).
- 181 41 Rousseeuw, P. J. & Kaufman, L. *Finding groups in data: An introduction to cluster analysis*.
 (John Wiley & Sons Hoboken, New Jersey, 2009).

182 **ACKNOWLEDGMENTS**

183 This study was supported in part by a National Research Foundation of Korea (NRF)
184 grant funded by the Korea government (MSIT) (2022R1C1C2003637) (to K.S.K.); Scientific
185 Research (KAKENHI) B 23H03497 (to S.I.); Grant-in-Aid for Transformative Research Areas
186 22H05215 (to S.I.); Grant-in-Aid for Challenging Research (Exploratory) 22K19829 (to S.I.);
187 AMED CREST 19gm1310002 (to S.I.); AMED Research Program on Emerging and Re-emerging
188 Infectious Diseases 22fk0108509 (to S.I.), 23fk0108684 (to S.I.), 23fk0108685 (to S.I.); AMED
189 Research Program on HIV/AIDS 22fk0410052 (to S.I.); AMED Program for Basic and Clinical
190 Research on Hepatitis 22fk0210094 (to S.I.); AMED Program on the Innovative Development and
191 the Application of New Drugs for Hepatitis B 22fk0310504h0501 (to S.I.); AMED Strategic
192 Research Program for Brain Sciences 22wm0425011s0302; AMED JP22dm0307009 (to K.A.);
193 JST MIRAI JPMJMI22G1 (to S.I.); Moonshot R&D JPMJMS2021 (to K.A. and S.I.) and
194 JPMJMS2025 (to S.I.); Institute of AI and Beyond at the University of Tokyo (to K.A.); Shin-Nihon
195 of Advanced Medical Research (to S.I.); SECOM Science and Technology Foundation (to S.I.);
196 The Japan Prize Foundation (to S.I.). The collaboration between R.N.T. and S.I. was supported
197 by a Royal Society International Exchange award (grant number IES-R3-193037).

198

199 **AUTHOR CONTRIBUTIONS**


500 SI and FM designed the research. YDJ carried out the computational analysis. SI and FM
501 supervised the project. All authors discussed the research and contributed to writing the
502 manuscript.

503

504 **COMPETING FINANCIAL INTERESTS**

505 The authors declare no conflicts of interest associated with this manuscript.


506



508

509 **Extended Data Fig. 1: Characterization of mpox virus infection dynamics. a**, Estimated viral
 510 load trajectory for mpox cases with lesion samples. The solid line is the estimated viral load
 511 trajectory under the best-fit fixed effect parameters. The shaded regions indicate 95% prediction
 512 intervals computed using a bootstrap approach. **b**, Distributions of estimates of the viral RNA
 513 load at symptom onset (upper panel) and distributions of estimates of the duration of viral
 514 shedding (lower panel). The vertical dashed lines indicate median values.


515



516

517 **Extended Data Fig. 2: Comparison between fixed-duration and testing-based rules for**
 518 **different groups.** The circles and triangles represent fixed-duration and testing-based rules,
 519 respectively. Each symbol represents the mean length of isolation using the strategy that
 520 minimizes unnecessarily prolonged isolation under the conditions that the risk of prematurely
 521 ending isolation is less than 5% and the infectious period after ending isolation is less than 1 day.
 522 Note that for testing-based rules, the interval between tests and the number of consecutive
 523 negative results necessary to end isolation were chosen to minimize the unnecessarily
 524 prolonged isolation period.

525



526

527

Extended Data Fig. 3: Comparison of mpox virus infection between lesion samples and

528

other samples. a, Estimated viral load trajectories for mpox cases with different samples. The

529

solid lines are estimated viral load trajectories for the best-fit parameters of fixed effect. The

530

shaded regions indicate 95% prediction intervals computed using a bootstrap approach. The

531

purple, yellow, orange, and grey colors correspond to lesion, upper respiratory, blood, and

532

semen samples, respectively. **b**, Distribution of viral RNA load with different samples at the end

533

of isolation. **c**, Proportion of infectious individuals with different samples (%) at the end of

534

isolation. Note that the optimal ending isolation period of 22 days under a fixed-duration rule was

535

used as the end of isolation. Color keys apply to all panels.